CIK 0001628171
- Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472029180
- Phone
- +1 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,328,124
- in 21 filings, $85.3M under 10b5-1 plans
Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-20 | Horning Sandra Director | Grant or award · Stock Option (Right to Buy) | +10,248 | 10,248 | ||
| 2024-06-20 | Horning Sandra Director | Grant or award | +4,800 | 95,287 | ||
| 2024-06-20 | Horning Sandra Director | Grant or award · Stock Option (Right to Buy) | +16,700 | 16,700 | ||
| 2024-06-20 | Patel Sushil Director | Grant or award | +4,800 | 20,500 | ||
| 2024-06-20 | Patel Sushil Director | Grant or award · Stock Option (Right to Buy) | +16,700 | 16,700 | ||
| 2024-06-20 | Borisy Alexis Director | Grant or award | +4,800 | 2,336,294 | ||
| 2024-06-20 | Borisy Alexis Director | Grant or award · Stock Option (Right to Buy) | +16,700 | 16,700 | ||
| 2024-06-20 | Kim Lorence H. Director | Grant or award | +4,800 | 70,500 | ||
| 2024-06-20 | Kim Lorence H. Director | Grant or award · Stock Option (Right to Buy) | +16,700 | 16,700 | ||
| 2024-06-20 | Weber Barbara Director | Grant or award | +4,800 | 20,625 | ||
| 2024-06-20 | Weber Barbara Director | Grant or award · Stock Option (Right to Buy) | +16,700 | 16,700 | ||
| 2024-06-20 | Borellini Flavia Director | Grant or award | +4,800 | 22,434 | ||
| 2024-06-20 | Borellini Flavia Director | Grant or award · Stock Option (Right to Buy) | +16,700 | 16,700 | ||
| 2024-06-20 | ANDERSON ELIZABETH M Director | Grant or award | +4,800 | 20,625 | ||
| 2024-06-20 | ANDERSON ELIZABETH M Director | Grant or award · Stock Option (Right to Buy) | +16,700 | 16,700 | ||
| 2024-06-17 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −11,950 | $37.39 | $447K | 311,885 |
| 2024-06-17 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −1,893 | $37.39 | $71K | 101,176 |
| 2024-06-17 | Horn Margaret A Chief Operating Officer | Sale 10b5-1 | −4,415 | $37.39 | $165K | 136,651 |
| 2024-06-17 | Kelsey Stephen Michael See Remarks | Sale 10b5-1 | −3,349 | $37.39 | $125K | 269,073 |
| 2024-06-17 | Cislini Jeff General Counsel | Sale 10b5-1 | −1,757 | $37.39 | $66K | 51,487 |
Page 25 of 29 · 569 trades